Baxter International Inc. · NYSE:BAX
Baxter International — Investor Day (May 2018)
14 slides from Baxter International's investor day presentation, May 21, 2018
Slide 1: Strategic Overview
STRATEGIC OVERVIEW Giuseppe Accogli SVP and President, Global Businesses May 21, 2018
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation includes forward-looking statements concerning Baxter’s financial results, R&D pipeline, including planned product launches (many of which are subject to regulatory approval) and results of clinical trials, business development activities, capital structure, c
Slide 3: Key Market Overview
Key Market Overview Baxter Market Size1 Growth2 Outlook4 Sustainable market growth of 3% - 4% supported by: Renal Care ~$14B ~4% ~5% Medically necessary products and therapies Acute Therapies ~$1B 7% - 8% 8% - 9% Rising prevalence of chronic Clinical Nutrition ~$4B 3% - 4% 4% - 5% disease and co
Slide 4: Our Strategy
Our Strategy Exceed our end-market growth by strengthening our portfolio and extending our impact through transformative innovation that spans prevention to recovery
Slide 5: Baxter's Strategic Growth Drivers
Baxter’s Strategic Growth Drivers Portfolio Innovation Market Development Enter Adjacencies ~$1.7B $150M $6B+ 2023 New Product Sales1 Strategic Growth Investments2 New Market Opportunities Executing on pipeline Expanding beyond the opportunities and Clinical Education Targeted core to unlock new Evi
Slide 6: Building A Culture Of Innovation
Portfolio Market Enter Building A Culture Of Innovation Innovation Development Adjacencies New Product Sales Building A Culture Of Innovation ~$1.7B Fueled By: ~$1.0B New Organizational New Talent Structure In Place ~$0.3B Resource Accelerated Pace Reallocation Of Innovation 2018 2020 2023 New Produ
Slide 7: Near-Term Launches
Portfolio Market Enter Near-Term Launches Innovation Development Adjacencies 2018 Launches 2019 Launches 2020 Launches ~$500M ~$400M ~$350M 2023 New Product Sales 2023 New Product Sales 2023 New Product Sales 2018 – 2020 Launches Drive $1.2+ Billion In 2023 Sales | 7
Slide 8: Evidence Generation
Portfolio Market Enter Evidence Generation Innovation Development Adjacencies $100M+ Investment In Evidence Generation In Progress 2017 - 20181 Future Theranova CRRT Oxiris Balanced Solutions Nutrition in Oncology Infection Prevention 2 Claims 6 Claims Numeta PIVA Point of Care Olimel N12 Theranova
Slide 9: Market Development
Portfolio Market Enter Market Development Innovation Development Adjacencies Clinical Nutrition Advanced Surgery Medication Delivery Investing in supplemental Program encouraging use of Surgeon-to-surgeon web based Description Parenteral Nutrition balanced fluids in fluid engagement platform awarene
Slide 10: Strategic Country Investments
Portfolio Market Enter Strategic Country Investments Innovation Development Adjacencies Japan currently represents only Significant emphasis and investment ~3% of Baxter overall sales will be placed on commercial opportunities in Japan across: Renal Care Advanced Surgery Acute Therapies Whereas Japa
Slide 11: Strategic Growth Initiatives
Portfolio Market Enter Strategic Growth Initiatives Innovation Development Adjacencies Organ Support Specialized Monitoring Therapies Non-Invasive Methods To Monitor Volume Neonatal Nutrition & Status And Guide Fluid Therapy Nutrition in Oncology Differentiated Drug Delivery Platforms Syringe & Pain
Slide 12: Transformative Innovation
Transformative Innovation Personalized Care Utilize Existing Technologies New Business Models Utilize installed base of ~800K New applications of Baxter’s Enable CKD1 and AKI2 electromechanical devices to innovative membrane management from early create therapy ecosystem technology diagnosis to reco
Slide 13: Strategy Overview Summary
Strategy Overview Summary Operating in critically-needed therapies that drive sustainable market growth over the LRP Strengthening the portfolio through innovation to deliver ~$1.7B of new product sales and geographic expansions in 2023 Unlocking $6B+ of additional addressable categories through mar
Slide 14: 2018 Investor Conference
— 2018 Investor Conference a